Skip to main content icon/video/no-internet

Germany has Europe's largest economy and is the second most populous nation in Europe. Like most highly developed nations, Germany is not a major producing nation of drugs such as marijuana, cocaine, or heroin; however, it is a source of synthetic drugs and precursor chemicals for South American cocaine processors. Rates of use in Germany are moderate by European standards. Based on United Nations (UN) estimates, slightly less than 5 percent of the population ages 18–64 use cannabis annually. Less than 1 percent of the adult population use cocaine, methamphetamine, or ecstasy annually, and between 0.15 and 0.30 percent of the population are annual opiate users. As in other western European nations, most opiate users in Germany use heroin.

Germany's policies and legislated control efforts pertaining to the use, possession, trafficking, and cultivation of various narcotics are considerably progressive when compared with many other countries. Only when they are compared with those of nations such as the Netherlands or Switzerland, might Germany's extant narcotics legislation be regarded as moderate/conservative. Germany has drug policies and legislation, for example, which provide for many policies viewed as progressive. These include syringe exchange programs and vending machines, safe-injection rooms, access to both methadone and heroin in addiction-treatment programs for intravenous drug abusers, prosecutor discretion to not prosecute those charged with possession of small amounts of drugs (especially cannabis) for personal use, the production of industrial hemp, as well as treatment alternatives to incarceration for convicted abusers and addicts. These policies sometimes conflict with the aims of nations that seek a more restrictive strategy for dealing with controlled substances, such as those of the United States. German narcotics legislation, however, has been amended to provide for mandatory minimum sentencing for those convicted of severe narcotics-related offenses such as the trafficking and production of significant amounts of a regulated or illicit substance. Such reforms have pleased those nations favoring a more stringent approach.

The Controlled Substances Legislative Act

Germany is a party to the Single Convention on Narcotic Drugs. German drug policy is controlled at the national level by the Betäubungsmittelgesetz (BtmG), or Controlled Substances Legislative Act. The BtmG was enacted in the early 1970s and has undergone amendments in 1982, 1994, and 2009. The BtmG shifts the emphasis from enforcement to harm reduction and treatment. The BtmG is the direct successor to the Opium Act of the German Reich, which first came into effect in December 1929. A result of the German defeat in World War I, this legislation placed German drug policy in compliance with the 1912 International Opium Convention as required by the Treaty of Versailles, as well as with other previous international efforts to combat the spread of narcotics, especially opium. Up until this time, the use of opium derivatives and cocaine in medicine were easily accessible and prevalent. This act mandated that the use of such substances only be allowed when prescribed by a doctor for medical treatment. However, after the passage of this act, it still remained possible to obtain heroin and other opium derivatives in German pharmacies. In 1941 amphetamines were included in the act as regulated substances. The Opium Law was dissolved on January 10, 1972, in conjunction with the ratification of the new narcotics act, the BtmG.

...

  • Loading...
locked icon

Sign in to access this content

Get a 30 day FREE TRIAL

  • Watch videos from a variety of sources bringing classroom topics to life
  • Read modern, diverse business cases
  • Explore hundreds of books and reference titles

Sage Recommends

We found other relevant content for you on other Sage platforms.

Loading